human microbiome Market

The human microbiome market is expected to reach US$ 4.84 billion by 2031 from US$ 1.07 billion in 2023; the market is estimated to register a CAGR of 20.8% during 2023–2031. Major factors driving the market growth significant investments by key market players and government initiatives. Further, the emergence of precision medicine is likely to boost the market during the forecast period. However, challenges during commercialization are among the market deterrents.

The human microbiome industry's growth, innovation, and market dynamics are greatly influenced by the investments made by major players in the market. Major players are engaged in making significant investments in research and development to create novel probiotics, diagnostics, and treatments based on the microbiome. These expenditures stimulate innovation, identifying new strains, modes of action, and medicinal uses. Clinical trials receive a large amount of funding, which is essential for demonstrating the effectiveness and safety of products based on the microbiome. A pioneer in microbiome mapping technology, Kanvas Biosciences, announced a US$ 12 million Pre-Series A funding round in June 2023. The company's proprietary platform technology, which has the potential to transform drug development for illnesses linked to the microbiome, will be further developed with the help of the investment. These partnerships make sharing resources, know-how, and technological advancements easier, speeding up product development. For instance, a new collaboration was announced between the world's largest food and beverage company, Nestlé, and a top-tier SFI research center, APC Microbiome Ireland, in July 2023. The collaboration centers on different aspects of the human microbiome and helps develop new products to enhance human health and wellness. As many as 120 companies are reportedly investing in microbiome analysis, and numerous startups are entering this field. Flagship Pioneering, Seventure Partners, and BioGaia are the most active investors. Thus, increase in investments by key players is likely drive the growth of market.

The comparative company analysis evaluates and categorizes the human microbiome market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global human microbiome market. The key market players are MaaT Pharma; Ferring Holdings SA; Finch Therapeutics Group Inc; AOBiome Therapeutics Inc.; Seres Therapeutics Inc; Merck & Co Inc; Yakult Honsha Co., Ltd; Rebiotix; Inc; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc.

The human microbiome market, based on type, is segmented into product and software and services. The product segment held a larger share of the human microbiome market in 2023, and it is expected to register a higher CAGR during 2023–2031. The human microbiome includes all microorganisms in and on the human body. These microbes have potential for use in disease management. Microbiome products show promise in treating severe conditions and personalizing therapy. The microbiota has been linked to neurological diseases, inflammatory diseases, and cancer.

Based on application, the market is segmented into therapeutics, diagnostics, and research. The therapeutics segment accounted for the largest share of the human microbiome market in 2023 The significant metabolic potential of gut microbes and their role in maintaining human health is emerging, with new possibilities to utilize them as therapeutic agents for addressing human disorders. In recent years, microbiome-based therapeutics, also known as microbiome modulators, have made rapid advances. Several promising candidates have moved forward through the clinical pipeline. For instance, in April 2023, Ferring Pharmaceuticals' VOWST, the first fecal microbiota product taken orally, was approved for preventing recurrence of Clostridioides difficile (C. difficile) infection in patients 18 years and older, following antibiotic treatment for recurrent infection.

Based on disease type, the human microbiome market is segmented into obesity, diabetes, autoimmune disorders, cancer, GIT disorders, and others. The GIT disorders segment held the largest share of the human microbiome market in 2023.

Various organic and inorganic strategies are adopted by companies operating in the human microbiome market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the human microbiome market are listed below.

• In March 2024, MaaT Pharma announced the launch of a retrospective multicenter trial called CHRONOS in Europe. Its objective is to provide the Company efficacy data for 3rd-line therapies for patients not receiving MaaT013 or any microbiome intervention. This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.
• In July 2021, Seres Therapeutics, Inc. and Nestlé Health Science entered into commercialization license agreement to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States (U.S.) and Canada.